These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins.
    Author: Wootton M, Walsh TR, Macfarlane L, Howe RA.
    Journal: J Antimicrob Chemother; 2010 Jan; 65(1):79-81. PubMed ID: 19915068.
    Abstract:
    OBJECTIVES: To assess the activity of mecillinam against two groups of Escherichia coli: (i) a selection of international isolates with mechanisms of resistance caused by the presence of defined beta-lactamases; and (ii) isolates resistant to third-generation cephalosporins referred from across Wales. METHODS: Antibiotic susceptibility testing with mecillinam, meropenem, amoxicillin, co-amoxiclav, cefotaxime, piperacillin/tazobactam, ciprofloxacin, nitrofurantoin, trimethoprim and gentamicin was performed using the BSAC agar dilution method against 30 international strains of E. coli with known beta-lactamase presence. Antibiotic susceptibility testing with mecillinam using the same method was performed against 325 regional isolates of E. coli resistant to third-generation cephalosporins. RESULTS: The susceptibility results showed that the only antibiotics to which the 30 international isolates were consistently susceptible were mecillinam (100%) and meropenem (100%), irrespective of the presence of beta-lactamases. Of the local isolates, 93.5% (304/325) were susceptible to mecillinam, having MICs < 8 mg/L. CONCLUSIONS: Our results show that mecillinam has excellent in vitro activity against a range of E. coli exhibiting beta-lactamase activity, some with the production of multiple beta-lactamases. It is time to further evaluate the clinical utility of mecillinam in the treatment of infections caused by such organisms.
    [Abstract] [Full Text] [Related] [New Search]